Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Pulmonary Tuberculosis III01:31

Pulmonary Tuberculosis III

Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
Tuberculosis01:23

Tuberculosis

Tuberculosis (TB) remains a significant global health concern, primarily targeting the lungs and spreading through airborne transmission. Infection begins when aerosolized droplet nuclei, expelled by an individual with active TB, are inhaled by another person. These microscopic particles carry Mycobacterium tuberculosis, the causative agent of TB. Upon reaching the alveoli, the bacilli are engulfed by alveolar macrophages. However, due to their specialized lipid-rich cell wall, these pathogens...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Assessing <i>Corynebacterium glutamicum</i> as a surrogate of <i>Mycobacterium tuberculosis</i> for DNA gyrase inhibitor design.

bioRxiv : the preprint server for biology·2026
Same author

Functional dissection of <i>Corynebacterium glutamicum</i> Wag31 domains for septal recruitment and polar distribution during the cell cycle.

mBio·2026
Same author

Monoclonal antibodies against nitrated nerve growth factor reveal an oxidation-dependent pathogenic hallmark in ALS.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

Structural basis of <i>Mycobacterium</i> Fluoroquinolone Resistance Protein D (MfpD), a versatile pathogeny protein from the <i>mfp</i> conservon of <i>Mycobacterium tuberculosis</i>.

bioRxiv : the preprint server for biology·2026
Same author

Structural basis for EtfD-mediated coupling of β-oxidation and the respiratory chain in mycobacteria.

The EMBO journal·2026
Same author

Mechanistic insights into SteAB regulation of cell wall hydrolase RipA in <i>Mycobacterium tuberculosis</i>.

mBio·2026
Same journal

Engineering cells for solid tumor therapy.

Trends in pharmacological sciences·2026
Same journal

Targeting developmental reprogramming: hPSC insights for cancer interception.

Trends in pharmacological sciences·2026
Same journal

July 2026 issue first authors.

Trends in pharmacological sciences·2026
Same journal

Chronobiomaterials for circadian-aligned brain therapeutics.

Trends in pharmacological sciences·2026
Same journal

Biosensors for translatable GPCR bias.

Trends in pharmacological sciences·2026
Same journal

ECM stiffness and epigenetics in organ fibrosis.

Trends in pharmacological sciences·2026
See all related articles

Related Experiment Video

Updated: Jun 30, 2026

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis
10:29

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

Published on: March 24, 2017

Rising standards for tuberculosis drug development.

Tanjore S Balganesh1, Pedro M Alzari, Stewart T Cole

  • 1AstraZeneca India, Bangalore - 560 024, India.

Trends in Pharmacological Sciences
|September 19, 2008
PubMed
Summary
This summary is machine-generated.

Developing new tuberculosis (TB) drugs is challenging due to the bacterium's resistance and patient co-infections like HIV and diabetes. New TB therapies must be safe for long-term use and compatible with other medications.

More Related Videos

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
09:57

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Published on: April 5, 2017

Related Experiment Videos

Last Updated: Jun 30, 2026

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis
10:29

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

Published on: March 24, 2017

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
09:57

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Published on: April 5, 2017

Area of Science:

  • Microbiology
  • Pharmacology
  • Infectious Diseases

Background:

  • Tuberculosis (TB) drug development faces unique challenges.
  • Intrinsic properties of Mycobacterium tuberculosis, including slow growth and phenotypic drug resistance, complicate treatment.
  • Increasing primary drug resistance necessitates novel therapeutic agents with new mechanisms of action.

Purpose of the Study:

  • To review the evolving clinical landscape of tuberculosis.
  • To outline considerations for defining the product profile of new TB drugs.
  • To discuss recent advancements in TB drug development.

Main Methods:

  • Literature review of TB clinical trends.
  • Analysis of drug development constraints.
  • Synthesis of information on new TB drug progress.

Main Results:

  • The clinical profile of TB patients is changing, with increased co-infections (e.g., HIV) and comorbidities (e.g., type-2 diabetes).
  • New TB drugs require a novel mode of action to combat resistance.
  • Safety and compatibility with co-administered therapies (e.g., antiretrovirals) are critical.

Conclusions:

  • The product profile for new TB drugs must account for the changing patient population and treatment complexities.
  • Addressing drug resistance and co-morbidities is essential for effective TB control.
  • Recent progress in TB drug development is promising but requires careful consideration of clinical realities.